Karyopharm Maintains FY 2023 Revenue Guidance of $145M-$160M (Consensus Of $151.31M), Including U.S. XPOVIO Net Product Revenue Guidance of $110M-$125M
Portfolio Pulse from Benzinga Newsdesk
Karyopharm Therapeutics has maintained its revenue guidance for FY 2023 at $145M-$160M, which is in line with the consensus of $151.31M. This includes U.S. XPOVIO net product revenue guidance of $110M-$125M.
November 02, 2023 | 11:38 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Karyopharm's maintained revenue guidance for FY 2023 aligns with market expectations, which could stabilize the company's stock price.
Karyopharm's revenue guidance for FY 2023 is in line with the market consensus, which indicates that the company's financial performance is as expected. This could stabilize the company's stock price in the short term as it reduces uncertainty for investors.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100